Home >> General Pharmaceuticals >> Housing >> Food & Beverage >>

Burkholderia Pseudomallei Infections - Pipeline Review, H2 2014

Published: Dec-2014 | Format: PDF | Global Markets Direct | Number of pages: 45 | Code: MRS - 18543


Global Markets Directs, Burkholderia Pseudomallei Infections Pipeline Review, H2 2014, provides an overview of the Burkholderia Pseudomallei Infectionss therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Burkholderia Pseudomallei Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Burkholderia Pseudomallei Infections and special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Scope

The report provides a snapshot of the global therapeutic landscape of Burkholderia Pseudomallei Infections
The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
The report reviews key players involved in the therapeutics development for Burkholderia Pseudomallei Infections and enlists all their major and minor projects
The report summarizes all the dormant and discontinued pipeline projects
A review of the Burkholderia Pseudomallei Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
A detailed assessment of monotherapy and combination therapy pipeline projects
Coverage of the Burkholderia Pseudomallei Infections pipeline on the basis of target, MoA, route of administration and molecule type
Latest news and deals relating related to pipeline products

Reasons to buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Develop strategic initiatives by understanding the focus areas of leading companies
Identify and understand important and diverse types of therapeutics under development for Burkholderia Pseudomallei Infections
Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
Devise corrective measures for pipeline projects by understanding Burkholderia Pseudomallei Infections pipeline depth and focus of Indication therapeutics
Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Content 

Table of Contents 2
List of Tables 4
List of Figures 4

Introduction 5
Global Markets Direct Report Coverage 5
Burkholderia Pseudomallei Infections Overview 6
Therapeutics Development 7
Pipeline Products for Burkholderia Pseudomallei Infections - Overview 7
Pipeline Products for Burkholderia Pseudomallei Infections - Comparative Analysis 8
Burkholderia Pseudomallei Infections - Therapeutics under Development by Companies 9
Burkholderia Pseudomallei Infections - Therapeutics under Investigation by Universities/Institutes 10
Burkholderia Pseudomallei Infections - Pipeline Products Glance 11
Early Stage Products 11
Burkholderia Pseudomallei Infections - Products under Development by Companies 12
Burkholderia Pseudomallei Infections - Products under Investigation by Universities/Institutes 13
Burkholderia Pseudomallei Infections - Companies Involved in Therapeutics Development 14
Bavarian Nordic A/S 14
Emergent BioSolutions Inc. 15
Evolva SA 16
Soligenix, Inc. 17
Syntiron LLC 18
Burkholderia Pseudomallei Infections - Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Target 20
Assessment by Mechanism of Action 22
Assessment by Route of Administration 24
Assessment by Molecule Type 26
Drug Profiles 28
Burkholderia pseudomallei vaccine - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
burkholderia vaccine - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
EV-035 - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
GC-072 - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
SGX-101 - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
SGX-942 - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
SGX-943 - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Small Molecules to Inhibit FtsZ Protein for Bacterial Infections - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Small Molecules to Inhibit InhA for Infectious Diseases - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Burkholderia Pseudomallei Infections - Recent Pipeline Updates 39
Burkholderia Pseudomallei Infections - Dormant Projects 41
Burkholderia Pseudomallei Infections - Discontinued Products 42
Burkholderia Pseudomallei Infections - Product Development Milestones 43
Featured News & Press Releases 43
Aug 14, 2014: US DTRA to fund preclinical work on Evolvas antibiotic GC-072 43
Feb 14, 2014: Soligenix Announces $300,000 NIAID SBIR Grant Award Supporting Further Evaluation of SGX943 as a Treatment for Melioidosis 43

Appendix 44
Methodology 44
Coverage 44
Secondary Research 44
Primary Research 44
Expert Panel Validation 44
Contact Us 45
Disclaimer 45

List of Tables
 

Number of Products under Development for Burkholderia Pseudomallei Infections, H2 2014 7
Number of Products under Development for Burkholderia Pseudomallei Infections - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 9
Number of Products under Investigation by Universities/Institutes, H2 2014 10
Comparative Analysis by Early Stage Development, H2 2014 11
Products under Development by Companies, H2 2014 12
Products under Investigation by Universities/Institutes, H2 2014 13
Burkholderia Pseudomallei Infections - Pipeline by Bavarian Nordic A/S, H2 2014 14
Burkholderia Pseudomallei Infections - Pipeline by Emergent BioSolutions Inc., H2 2014 15
Burkholderia Pseudomallei Infections - Pipeline by Evolva SA, H2 2014 16
Burkholderia Pseudomallei Infections - Pipeline by Soligenix, Inc., H2 2014 17
Burkholderia Pseudomallei Infections - Pipeline by Syntiron LLC, H2 2014 18
Assessment by Monotherapy Products, H2 2014 19
Number of Products by Stage and Target, H2 2014 21
Number of Products by Stage and Mechanism of Action, H2 2014 23
Number of Products by Stage and Route of Administration, H2 2014 25
Number of Products by Stage and Molecule Type, H2 2014 27
Burkholderia Pseudomallei Infections Therapeutics - Recent Pipeline Updates, H2 2014 39
Burkholderia Pseudomallei Infections - Dormant Projects, H2 2014 41
Burkholderia Pseudomallei Infections - Discontinued Products, H2 2014 42

List of Figures

Number of Products under Development for Burkholderia Pseudomallei Infections, H2 2014 7
Number of Products under Development for Burkholderia Pseudomallei Infections - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 9
Comparative Analysis by Early Stage Products, H2 2014 11
Assessment by Monotherapy Products, H2 2014 19
Number of Products by Top 10 Targets, H2 2014 20
Number of Products by Stage and Top 10 Targets, H2 2014 20
Number of Products by Top 10 Mechanism of Actions, H2 2014 22
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2014 22
Number of Products by Top 10 Routes of Administration, H2 2014 24
Number of Products by Stage and Top 10 Routes of Administration, H2 2014 24
Number of Products by Top 10 Molecule Types, H2 2014 26
Number of Products by Stage and Top 10 Molecule Types, H2 2014 26

Inquiry For Buying

Please fill your details below, to inquire about this report:
Indicates required fields

Request Sample

Please fill your details below, to receive sample report:
Indicates required fields

  • Payment Mode

COVID-19 Pandemic Impacts

Our Analysts and Consultants are working ceaselessly to congregate, identify, analyze, and portray the Actual Impacts of COVID-19 Global Pandemic in each of our published as well as ongoing research reports to Redefine and Revise Current and Future Market Trends, Growth Rates, And Market Size Projections across the Globe as well as in different Regions and individual Countries.

Single User | $(USD)2000 View Pricing